# Novartis Pays $2B to Move Past Its Own Failed Cancer Drug - Date: 2026-03-22 - Category: Biotech & Life Sciences The pharma giant is acquiring Synnovation's mutant-selective PI3Kα inhibitor SNV4818, a bet that precision targeting can solve the tolerability problems that have haunted its first-generation Piqray. ---